Head-to-head evidence
H002 vs SH-1028
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
H002
Developed by RedCloud Bio
NCT05519293 · Phase 1/2 · status unknown
A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.
SH-1028
Developed by Nanjing Sanhome Pharmaceutical
NCT04239833 · Phase 3 · status unknown
In this randomized, double-blind, active-controlled Phase 3 trial in patients with EGFR-mutated non-small-cell lung cancer, SH-1028 significantly extended progression-free survival compared with gefitinib, the standard EGFR-targeted therapy (median 19.3 months vs 9.8 months).
Next expected readout: February 2028 · NCT06080776 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: H002's landscape · SH-1028's landscape